Mass Tort Marketing Agency
Zantac mass tort lead generation for attorneys

Mass Tort Lead Generation for Attorneys

Zantac lead generation for plaintiff firms

Pre-screened Zantac (ranitidine) NDMA exposure claimants with actively litigated cancer diagnoses, delivered to firms positioned in remaining viable venues.

Zantac litigation status & sources

Federal claims dismissed or limited

Status verified on against primary sources · next check due

As of Nov 2026, federal MDL 2924 (S.D. Fla., Judge Robin L. Rosenberg) remains dismissed after December 2022 expert exclusions; no Eleventh Circuit decision on the October 2025-argued appeal was found. Delaware's Superior Court dismissed the remaining state cases in April 2026.

Zantac is not currently an open, consolidated proceeding. Confirm filing posture and case criteria with counsel before launching or continuing a campaign.

Proceeding
MDL 2924 (S.D. Fla.)
Judge Robin L. Rosenberg
Proceeding
In re Zantac (Ranitidine) Litigation, C.A. No. N22C-09-101 ZAN (Delaware Superior Court)
Judge Francis J. Jones Jr.
Pending actions
806
JPML Pending MDL Dockets by District, report date 11/2/2026

Key dates

  1. Judge Rosenberg excluded plaintiffs' general-causation experts in MDL 2924, leading to dismissal of the federal designated-cancer claims.
  2. The Delaware Supreme Court reversed the Superior Court's ruling admitting plaintiffs' experts and remanded.
  3. The Eleventh Circuit heard oral argument in the appeal of the MDL 2924 expert-exclusion ruling on Oct. 10, 2025.
  4. Delaware Superior Court Judge Jones dismissed the remaining Zantac cases, finding plaintiffs could not prove causation and were not entitled to new expert disclosures.

Sources

Marketing information for law firms, not legal advice. Litigation status changes; confirm filing posture, case criteria and deadlines with counsel before launching or continuing a campaign. How we source and date this: editorial standards.

Why this docket

Why Zantac matters right now

The federal MDL was dismissed under Daubert, but state-court Zantac litigation continues in Delaware, California, Illinois, and other venues — and several manufacturers have entered partial settlement frameworks. The docket favors firms with a sharp venue strategy and tight diagnosis-period screening. We deliver claimants pre-filtered against current viable venues and the specific cancer diagnoses still being litigated.

Our screening criteria

What we filter for before a lead reaches your intake

We screen against the public eligibility window for the Zantac docket plus any firm-specific retainer criteria you set. Leads that fail any criterion are flagged and routed out — not delivered to you.

  • Documented Zantac (ranitidine) usage with duration and frequency
  • Diagnosis of bladder, gastric, esophageal, liver, or pancreatic cancer (and case-by-case other NDMA-linked cancers)
  • Usage timeline before manufacturer recall (April 2020)
  • Residence in or filing eligibility for a viable state-court venue
  • No prior representation or settlement on the same claim

What you get

Built for Zantac acquisition partners

Exclusive, not shared

Every lead is routed to one firm only. We don't sell the same claimant to three competing firms — your intake team won't be racing competitors for the signature.

Pre-screened to your criteria

Before any lead reaches your intake, we screen against the docket's eligibility window, exposure duration, diagnosis, and any firm-specific retainer requirements you set.

Live transfer or scheduled delivery

Hot leads transfer live to your intake line during business hours. Off-hours leads queue into your CRM with full intake notes for next-business-day follow-up.

Compliance-vetted creative

Every ad creative and landing page is reviewed against TCPA, state bar advertising rules, FTC, and platform-specific policies before campaigns go live.

Specific to the Zantac docket

  • Usage-duration verification (prescription vs OTC, dates, frequency)
  • Diagnosis confirmation collected at intake
  • State-of-residence filtering against viable venue list
  • Cancer-type categorization for case-value triage
  • Prior-recall-period confirmation
  • Live transfer or CRM-queued delivery

Pricing

How Zantac lead pricing works

Zantac pricing reflects the venue-narrow nature of the docket. Claimants filing in viable state-court venues with the strongest diagnoses (bladder, gastric) command higher prices; pancreatic, liver, esophageal cases price tier-two. Both cost-per-qualified-lead and cost-per-signed-retainer models are available.

Ready to source Zantac claimants?

Get a docket-fit review for your firm

15 minutes. No pitch deck. We walk through which campaigns make sense for your state, what pricing would look like for Zantac, and what we would avoid.

Ready to review your next mass tort campaign?

Tell us about your firm, target cases, and intake capacity. A strategist will respond in under 5 minutes during business hours with practical next steps.

Speed-to-lead is the largest single lever in intake conversion: the gap between a 5-minute and a 30-minute callback is measured in retainers lost, not opportunities lost. The same clock is running on the torts you have not claimed yet.

Built for personal injury firms, intake teams, and mass tort dockets

By submitting this form, you consent to being contacted by Mass Tort Marketing Agency regarding lead generation services. Your information is confidential and will never be shared with competing firms.